Ampella Mining Limited

MorphoSys AG (FRA:MOR) MorphoSys to Accelerate the Expansion and Advancement of its Proprietary Pipeline

MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment) announced today that the 3-for-1 stock split of the MorphoSys share, which was resolved by the Company's shareholders at the Annual Shareholder Meeting on May 14, 2008, will be implemented on December 23, 2008. The first day of trading on a split-adjusted basis will be December 23, 2008.

MorphoSys AG (FRA:MOR) First HuCAL-based Antibody to Enter Clinical Trial in Second Indication

MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) today appointed Dr Arndt Schottelius (42), as its first Chief Development Officer, responsible for coordinating the Group's expanding therapeutic antibody development activities including pre-clinical and clinical drug development. Dr Schottelius joins MorphoSys from Genentech Inc., South San Francisco, where he served as the Director of Immunology, Tissue Growth & Repair Early Development and most recently as Medical Director, Immunology Development, directing late-stage clinical development studies for the anti-CD20 antibodies Rituximab and Ocrelizumab in rheumatoid arthritis. Prior to his position at Genentech, Dr Schottelius held science and management positions in immunology research at Berlex Biosciences, CA, USA, and Schering AG, Berlin, Germany. The appointment of Dr Schottelius will take effect on December 29, 2008.

MorphoSys AG (FRA:MOR) Improvements to Result in Considerable Time Savings, Higher Diversity, Affinities and Expression Rates

MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that the Company has been recognized by the World Economic Forum as a Technology Pioneer 2009. The World Economic Forum has selected 34 companies out of more than 320 applications from 15 countries for their accomplishments as innovators, and their work's current and future impact on business and society.

MorphoSys AG (FRA:MOR) Combination of Proprietary Drug Targets and Unique Technologies to Create Range of New Therapeutic Antibodies

MorphoSys AG (FRA:MOR) IP Position around MorphoSys's MOR103 Program Significantly Strengthened

MorphoSys AG (FRA:MOR) MorphoSys AG / Voting rights: Publication by MorphoSys AG pursuant to § 26 para. 1 WpHG regarding the release of a voting rights announcement pursuant to § 21 para. 1 WpHG with the aim of a Europe-wide distribution Publication pursuant to §26 sect.1 WpHG (the German Securities Trading Act) processed and transmitted by Hugin. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------

MorphoSys AG (FRA:MOR) MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) and Wacker Chemie AG are intensifying their cooperation in the use of WACKER's prokaryotic secretion technology. The two companies have signed a new agreement precisely defining areas of use and production limits under which MorphoSys will continue to use the secretion system on a research scale. As a result, MorphoSys will now be able to use the WACKER technology for both the early development phase of therapeutic projects as well as the production of diagnostic and research antibodies. If the agreed quantity limits are exceeded at MorphoSys, WACKER is able to provide a seamless transition to large-scale manufacturing services.